Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount

Surgical Neurology International

Volumn 4, Issue SUPPL5, 2013, Pages

  Epstein, Nancy ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b Long Island Neurosurgical Associates   (United States)

Author keywords

"off label"; Adverse events; BMP INFUSE; fusions; morbidity; spinal surgery

Indexed keywords

AMPLIFY; COLLAGEN SPONGE; CORTICOSTEROID; INFUSE; METHYLPREDNISOLONE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ARACHNOIDITIS; ARTICLE; BONE MALFORMATION; BONE PAIN; BONE TRANSPLANTATION; CANCER RISK; COST BENEFIT ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPHAGIA; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEMATOMA; HETEROTOPIC OSSIFICATION; HETEROTOPIC RETROPERITONEAL OSSIFICATION; HUMAN; ILIAC CREST; INFECTION; INTERVERTEBRAL DISK DEGENERATION; INTUBATION; LUMBAR TAPERED FUSION DEVICE SYSTEM; MORBIDITY; NEOPLASM; NEUROLOGIC DISEASE; NEUROSURGERY; NONHUMAN; OFF LABEL DRUG USE; OSTEOLYSIS; PAIN; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PSEUDARTHROSIS; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; RADICULITIS; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; RETROGRADE EJACULATION; RISK BENEFIT ANALYSIS; SEROMA; SIDE EFFECT; SOFT TISSUE INFLAMMATION; SPINE FUSION; SPINE FUSION IMPLANT; SPINE SURGERY; SPONDYLOLISTHESIS; SURGICAL INFECTION; SWELLING; THROMBOEMBOLISM; TISSUE ENGINEERING; TRACHEOSTOMY; URINE RETENTION; VISUAL ANALOG SCALE; WEIGHT REDUCTION;

EID: 84887126400     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.114813     Document Type: Article

References (21)

1. Arts MP, Kols NI, Onderwater SM, Peul WC. Clinical outcome of instrumented fusion for the treatment of failed back surgery syndrome: A case series of 100 patients. Acta Neurochir (Wien) 2012;154:1213-7.
2. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J 2011;11:471-91.
3. Carragee EJ, Mitsunaga KA, Hurwitz EL, Scuderi GJ. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: A cohort controlled study. Spine J 2011;11:511-6.
4. Chrastil J, Patel AA. Complications associated with posterior and transforaminal lumbar interbody fusion. J Am Acad Orthop Surg 2012;20:283-91.
5. Comer GC, Smith MW, Hurwitz EL, Mitsunaga KA, Kessler R, Carragee EJ. Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: A 10-year cohort controlled study. Spine J 2012;12:881-90.
6. Dagostino PR, Whitmore RG, Smith GA, Maltenfort MG, Ratliff JK. Impact of bone morphogenetic proteins on frequency of revision surgery, use of autograft bone, and total hospital charges in surgery for lumbar degenerative disease: Review of the Nationwide Inpatient Sample from 2002 to 2008. Spine J 2013. [In Press]
7. Deutsch H. High-dose bone morphogenetic protein-induced ectopic abdomen bone growth. Spine J 2010;10:e1-4.
8. Devine JG, Dettori JR, France JC, Brodt E, McGuire RA. The use of rhBMP in spine surgery: Is there a cancer risk? Evid Based Spine Care J 2012;3:35-41.
9. Epstein NE. Spine surgery in geriatric patients: Sometimes unnecessary, too much, or too little. Surg Neurol Int 2011;2:188.
10. Epstein NE. Pros, cons, and costs of INFUSE in spinal surgery. Surg Neurol Int 2011;2:10.
11. Epstein NE. Commentary on research of bone morphogenetic protein discussed in review article: Genetic advances in the regeneration of the intervertebral disc. Surg Neurol Int 2013;4(Suppl 2):S106-8.
12. Epstein NE, Schwall GS. Costs and frequency of "off-label" use of INFUSE for spinal fusions at one institution in 2010. Surg Neurol Int 2011;2:115.
13. Epstein NE, Hood DC. "Unnecessary" spinal surgery: A prospective 1-year study of one surgeon's experience. Surg Neurol Int 2011;2:83.
14. Even J, Eskander M, Kang J. Bone morphogenetic protein in spine surgery: Current and future uses. J Am Acad Orthop Surg 2012;20:547-52.
15. Gamache FW. The value of "another" opinion for spinal surgery: A prospective 14-month study of one surgeon's experience. Surg Neurol Int 2012;3(Suppl 5):S350-4.
16. Glassman SD, Carreon LY, Campbell MJ, Johnson JR, Puno RM, Djurasovic M, et al. The perioperative cost of INFUSE bone graft in posterolateral lumbar spine fusion. Spine J 2008;8:443-8. (Pubitemid 351608965)
17. Health Quality Ontario. Bone morphogenetic proteins and spinal surgery for degenerative disc disease: An evidence-based analysis. Ont Health Technol Assess Ser 2004;4:1-16.
18. Maerz T, Herkowitz H, Baker, K. Genetic Advances in the Regeneration of the Intervertebral Disc. Surg Neurol Int, 2013;4(Suppl 2):S94-105.
19. Moatz B, Tortolani PJ. Transforaminal lumbar interbody fusion and posterior lumbar interbody fusion utilizing BMP-2 in treatment of degenerative spondylolisthesis: Neither safe nor cost effective. Surg Neurol Int 2013; 4(Suppl 2):S67-73.
20. Tan Y, Montgomery SR, Aghdasi BG, Inoue H, Kaner T, Tian H, et al. The effect of corticosteroid administration on soft tissue inflammation associated with rhBMP-2 use in a rodent model of inflammation. Spine 2012. [In Press].
21. Woo EJ. Recombinant human bone morphogenetic protein-2: Adverse events reported to the Manufacturer and User Facility Device Experience database. Spine J 2012;12:894-9.